Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol CD82 contributors: mct/ - updated : 19-11-2018
HGNC name CD82 molecule
HGNC id 6210
DNA
TYPE functioning gene
STRUCTURE 54.20 kb     10 Exon(s)
regulatory sequence Promoter
text structure
  • ATF3 bound to the promoter of the CD82 gene
    • MAPPING cloned Y linked N status confirmed
    Map pter - D11S1330 - D11S905 - EXT2 EXT2 - [CD82 - D11S1361 - D11S1344 ] - D11S1357 - D11S3979 - D11S913 - cen
    Text [TSG11G ]
    RNA
    TRANSCRIPTS type messenger
    identificationnb exonstypebpproduct
    ProteinkDaAAspecific expressionYearPubmed
    9 - 1640 - 242 - 2002 11746987
    10 - 1715 - 267 - 2002 11746987
    EXPRESSION
    Type widely
       expressed in (based on citations)
    organ(s)
    SystemOrgan level 1Organ level 2Organ level 3Organ level 4LevelPubmedSpeciesStageRna symbol
    Digestiveintestinelarge intestinecolon highly
    Lymphoid/Immunespleen   highly Homo sapiens
     thymus   highly
     tonsils   highly
    Reproductivefemale systemplacenta  highly Homo sapiens
     male systemprostate  highly Homo sapiens
    Urinarykidney   highly Homo sapiens
    tissue
    SystemTissueTissue level 1Tissue level 2LevelPubmedSpeciesStageRna symbol
    Muscularstriatumskeletal highly
    cell lineage
    cell lines
    fluid/secretion
    at STAGE
    PROTEIN
    PHYSICAL PROPERTIES
    STRUCTURE
    motifs/domains
  • four hydrophobic and presumably transmembrane domains (4TM)
  • one large extracellular hydrophobic domain
  • three potential N-glycosylation sites
  • C-terminal region critical for its metastasis suppressor function, C-terminal cytoplasmic region regulates internalization of CD82, and contributes to postendocytic trafficking of the protein
    • conjugated GlycoP
    HOMOLOGY
    interspecies homolog to murine Kai1
    Homologene
    FAMILY
  • TM4 superfamily (TM4SF)
  • tetraspanin transmembrane protein superfamily
    • CATEGORY tumor suppressor
    SUBCELLULAR LOCALIZATION     plasma membrane
        intracellular
    intracellular,cytoplasm,organelle,endosome
    intracellular,cytoplasm,organelle,lysosome
    text
  • in late endosomes and lysosomes
    • basic FUNCTION
  • associating with CD4 or CD8 and delivering costimulatory signals for the TCR/CD3 pathway
  • may inhibit cell motility by regulating the biological activities of its associated proteins and/or reorganizing plasma membrane microdomains
  • prostate-specific tumor metastasis suppressor gene
  • lipid-dependent endocytosis drives CD82 trafficking to late endosomes and lysosomes, and CD82 reorganizes tetraspanin-enriched microdomains and lipid rafts through redistribution of cholesterol
  • role for CD82 in promotion of cell proliferation and mammary gland hyperplasia by the AMFR ubiquitin ligase
  • inhibit cancer metastasis without affecting primary tumorigenicity
  • metastasis suppressor implicated in biological processes ranging from fusion, adhesion and migration to apoptosis and cell-morphology alterations
  • induces autophagy through phosphorylation of extracellular signal-related kinases rather than that of AKT1
  • involved in the EPAS1 specific target gene and may be responsible for the specific role of EPAS1 in endothelial cells
  • downstream target and an effector of NDRG1, suggesting the concerted regulatory mechanism and activity of these metastasis suppressor genes
  • tetraspanin membrane protein functioning as a metastasis suppressor in many types of cancers and has been shown to regulate cell adhesion properties
  • modulatory role of CD82 in endocytic trafficking of EGF receptor
  • is a novel regulator of ligand-induced ubiquitylation of EGF receptor
  • CD82 and KISS1 are implicated in the pathogenesis and maintenance of endometriosis
    • CELLULAR PROCESS
    PHYSIOLOGICAL PROCESS
    PATHWAY
    metabolism
    signaling
    a component
    INTERACTION
    DNA
    RNA
    small molecule
    protein
  • interacting with DARC (leading to inhibition of tumor cell proliferation and induction of senescence by modulating the expression of TBX2 and p21)
  • CD82-MET complex inhibits HGF-induced cancer cell migration by the inactivation of small GTP-binding proteins of the Rho family via MET adapter proteins
  • ATF3 modulated CD82 transcription through cooperation with other endogenous transcription factor as co-activator (ATF3-JunB) or co-repressor (ATF3-NFKB)
  • functional downstream target of the NDRG1 pathway
  • new regulator of CBL, which discriminatively controls the activity of this E3 ubiquitin ligase toward heparin-binding ligand-EGFR pairs
  • CD82 regulated BCL2L12 expression via STAT5A and AKT1 signaling and stimulated proliferation and engrafting of leukemia cells
  • CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of CDH2
  • PPFIA1 is a novel regulator of CD82, linking PPFIA1 to the cancer cell invasion and metastasis pathways
    • cell & other
    REGULATION
    activated by by EPAS1, but not by HIF1A, in response to hypoxia
    NDRG1 that upregulated CD82 expression through modulation of ATF3 signaling in prostate cancer cells
    Other interaction with DARC is essential for the function of CD82 as a suppressor of metastasis
    ASSOCIATED DISORDERS
    corresponding disease(s)
    Other morbid association(s)
    TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
    constitutional     --over  
    on T cells (enhancement of cell-cell interaction through LFA1 and ICAM1)
    tumoral     --low  
    in several types of cancer (in cervical carcinoma), in metastatic progression
    tumoral   deletion    
    in prostate cancer with metastasis
    tumoral     --over  
    in non-small cell lung carcinoma cells suppresses the tumor invasiveness and metastatic potential by inducing MMP9 inactivation via the up-regulation of TIMP1
    constitutional     --over  
    in ischemic tissues, suggesting that it is a hypoxia target gene (
    tumoral     --low  
    in melanoma cell lines is related to LOH or allelic imbalance, but not to methylation of CD82 gene region
    constitutional     --over  
    may also cause alterations in extracellular matrix-binding integrin, and also may support the pathologic angiogenesis of CD151
    Susceptibility
    Variant & Polymorphism
    Candidate gene
    Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancermetastases 
    targeting as a therapeutic approach for the treatment of a variety of metastatic cancers
    cancerhemopathy 
    CD82 and BCL2L12 may be promising therapeutic targets in AML
    ANIMAL & CELL MODELS